Lates News

According to the AI Express of Every Economy, on April 26, Dongwu Securities issued a research report giving a "buy" rating to Minsheng Health (301507.SZ). The main reasons for the rating include: 1) The main business is growing steadily as scheduled, with significant incremental growth after the consolidation of Zhongke Jiayi; 2) Thanks to the positioning of 21Jinweita OTC, new products (such as Xiaojinweita), and expansion of specifications, we expect the product series to achieve a growth rate of 5% to 10% in terms of quantity/sales in 2026; the main business income of vitamins and minerals achieves 10% growth. (Daily Economic News)